D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Duopharma Biotech Bhd
Accounts Payable Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Accounts Payable
myr107.1m
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
19%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Accounts Payable
myr11.7m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
23%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Accounts Payable
myr179.9m
CAGR 3-Years
16%
CAGR 5-Years
7%
CAGR 10-Years
8%
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Accounts Payable
myr19.2m
CAGR 3-Years
4%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Accounts Payable
myr29.4m
CAGR 3-Years
21%
CAGR 5-Years
4%
CAGR 10-Years
3%
K
Kotra Industries Bhd
KLSE:KOTRA
Accounts Payable
myr16.2m
CAGR 3-Years
3%
CAGR 5-Years
-2%
CAGR 10-Years
-2%

See Also

What is Duopharma Biotech Bhd's Accounts Payable?
Accounts Payable
107.1m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Accounts Payable amounts to 107.1m MYR.

What is Duopharma Biotech Bhd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
19%

Over the last year, the Accounts Payable growth was -16%. The average annual Accounts Payable growth rates for Duopharma Biotech Bhd have been -6% over the past three years , -4% over the past five years , and 19% over the past ten years .

Back to Top